Table 3.

Primary samples derived of myeloma patients

Patient#	Sample#	Age	Gender	Ig subtype	Stage	Therapies	FISH
1	1	64	f	IgG lambda	III A	None	Tri9q
	2	64	f	IgG lambda	III A	3× RADa	Tri9q
2	3	50	m	IgG kappa	III A	Dexab 4× RAD 2× HD-Melc Lend	Normal
3	4	73	m	IgG kappa	I A	None	Hyperdiploide CMYC-Rearrangement
4	5	58	f	IgG lambda	I A	None	Amp1q21
5	6	78	f	IgG lambda	II A	None	–
6	7	72	m	IgG kappa	I A	None	–
7	8	43	m	IgA kappa	III A	None	Hyperdiploid
8	9	68	f	IgG kappa	III A	None	Hyperdiploid
9	10	49	f	IgG kappa	III A	None	Tri9q
10	11	61	m	Kappa LC	III B	3× ID > 2× HD-Mel; VRCDe > HD-Mel; VRCD	Normal
11	12	67	m	IgG lambda	II A	None	Hyperdiploid
12	13	62	m	Kappa LC	II A	None	Tri1q

^aradiation

^bdexamethason

^chigh-dose melphalan

^dlenalodimide

^ebortezomib dexamethasone thalidomide cyclophosphamide